Amptiv

Jon Bell

CEO
Amptiv
  • Working to unlock therapeutic mRNA performance with novel chemical modifications.
  • Amptiv’s core platform uses a post-transcriptional chemical modification system that bypasses the legacy constraints of enzymatic mRNA production. This system allows for the addition of a wide range of chemical modifications to optimize mRNA performance.
  • Collaborating across the industry to enhance mRNA for a variety of applications
  • Proud to be a part of AMM and help realize the full potential of of mRNA therapeutics to improve human health